Following its acquisition of Genentech, Roche has announced that Pascal Soriot, currently head of Roche's commercial pharmaceutical operations, will become Genentech's CEO, effective May 1, 2009. Soriot succeeds Arthur Levinson, chairman and CEO of Genentech since 1995. Levinson will retain his position as chairman.
Alnara Pharmaceuticals, a pharma manufacturer focused on the treatment of metabolic diseases, announced the promotion of Robert Gallotto to chief business officer. Gallotto was previously SVP, operations and corporate development.